Canadian Retina Society

Systemic medications and the retina/ocular medication to treat retinal disease

Sunday, 16 June 2013, 1330-1500
Lachine/Lasalle

Objectives
At the end of this session, participants will be able to:

  • Differentiate systemic medication with risk of retinal toxicity
  • Develop an approach to effectively monitor for retinal toxicity of systemic medication.
  • Describe current practice in the use of intraocular medication to treat retinal disease.


Guest
William F. Mieler, MD
Moderators
Phil Hooper
Alan Cruess

1330Introduction
1335Ocular complications of systemic medication
William F. Mieler
1350Discussion
1355Effectiveness of the multifocal electroretinogram for early detection of hydroxychloroquine and chloroquine retinal toxicity
Jennifer Gao, Kevin Leonard, John Hamilton, Stuart Coupland, Chloe Gottlieb
1400Discussion
1402A direct comparison of spectral domain optical coherence tomography (SD-OCT) and multifocal electroretinography (mfERG) findings in hydroxychloroquine retinopathy
Mark E. Seamone, Katherine Milton, Micheline Deschenes, Michael Fielden, Amin Kherani, Geoff Williams
1407Discussion
1409Experiences with the dexamethasone intravitreal implant
Ravinder D. Bhui, Micah Luong, Irfan N. Kherani, Micheline C. Deschenes, Michael Fielden, Geoff Williams, Amin Kherani, Wai-Ching Lam
1414Discussion
1416Resistance of ocular flora to gatifloxacin in patients undergoing intravitreal injections - a case-control study
Stephen J. Dorrepaal, Jeffrey Gale, Sherif El-Defrawy, Sanjay Sharma
1421Discussion
1423A prospective multicentre randomized clinical trial comparing topical nepafenac sodium 0.1% versus intraoperative intravitreal triamcinolone acetate versus placebo in vitrectomy for macular edema
Lei Di (Lily) Zhao, Wai-Ching Lam, Efrem Mandelcorn, Peter Kertes, Robert Devenyi, Mark Mandelcorn
1428Discussion
1430Aqueous cytokine levels as predictors of treatment response to ranibizumab in diabetic macular edema
Roxane J. Hillier, Elvis Ojaimi, Alan Berger, Filiberto Altomare, Shelley R. Boyd, Farzin Forooghian, David T. Wong, Louis Giavedoni, Radha Kohly, Kenneth Eng, Peter Kertes, Rajeev Muni
1435Discussion
1437Role of bevacizumab in persistent and recurrent central serous chorioretinopathy
Hayat A. Khan, Mohamed K. Tameesh
1442Discussion
1444Systemic absorption of intravitreal bevacizumab and ranibizumab in humans treated for diabetic macular edema
Davin Johnson, Edward B. Moss, Yat Tse, Stephen Pang, Ashley Brissette, Sanjay Sharma
1449Discussion
1552Concluding discussion

William F. Mieler
William F. Mieler, MD